A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia

The primary objective of this Phase 3, randomized, double-blind, placebo-controlled study is to evaluate the **efficacy** of MK-0616 compared with placebo on the mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24. This is clinically relevant as LDL-C is a major risk factor for cardiovascular diseases, and effective management of LDL-C levels is crucial in reducing cardiovascular risk in patients with **hypercholesterolemia**. Additionally, the study aims to assess the safety and tolerability of MK-0616.

Secondary objectives include evaluating the efficacy of MK-0616 compared with placebo on:

• Mean percent change from baseline in LDL-C at Week 52.
• Mean percent change from baseline in non-high-density lipoprotein cholesterol (non-HDL-C) at Week 24.
• Mean percent change from baseline in apolipoprotein B (ApoB) at Week 24.
• Percent change from baseline in lipoprotein(a) [Lp(a)] at Week 24.
• The proportion of participants achieving LDL-C levels of less than 70 mg/dL and a reduction of 50% or more from baseline at Week 24.
• The proportion of participants achieving LDL-C levels of less than 55 mg/dL and a reduction of 50% or more from baseline at Week 24.

The clinical trial involves a total of **2360 participants** diagnosed with **hypercholesterolemia**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected based on specific inclusion criteria, such as having a history of a major atherosclerotic cardiovascular disease (ASCVD) event or being at intermediate to high risk for developing a first major ASCVD event. Additionally, participants were required to have specific levels of LDL-C and to be on a stable dose of lipid-lowering therapies, such as statins, for at least 30 days prior to screening. The trial includes individuals who are either treated with moderate or high-intensity statins, those with documented intolerance to higher doses, or those not receiving statins due to intolerance. The study population also considers vulnerable groups, ensuring a comprehensive evaluation of the efficacy and safety of the investigational drug MK-0616 compared to placebo. Lifestyle factors such as diet and physical activity were not specified in the available data.

The clinical trial is a **Phase 3**, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of MK-0616 in adults with **hypercholesterolemia**. The trial aims to assess the mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24, alongside evaluating the safety and tolerability of MK-0616. The study is expected to last approximately 52 weeks, with participant involvement spanning the same duration. The trial will commence with a screening visit to determine eligibility based on specific inclusion criteria, such as a history of major atherosclerotic cardiovascular disease (ASCVD) events or an intermediate to high risk for such events, and LDL-C levels meeting predefined thresholds. Participants must be on a stable dose of lipid-lowering therapies for at least 30 days prior to screening.

Following the screening, eligible participants will be randomized to receive either MK-0616 or a placebo, administered orally in the form of a film-coated tablet. The primary endpoint will be assessed at Week 24, with secondary endpoints evaluated at Week 52, including changes in non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and lipoprotein A [Lp(A)]. Regular follow-up visits will be scheduled to monitor participants' health, adherence to the study protocol, and any adverse events. The end-of-study visit will conclude the trial, where final assessments will be conducted to gather comprehensive data on the primary and secondary endpoints.

Participants may be withdrawn from the study if they experience significant adverse events, fail to adhere to the study protocol, or if the investigator deems it necessary for their safety. The trial is not categorized as low intervention, and it is crucial to maintain the integrity of the double-blind design throughout the study duration. The estimated recruitment start date is September 25, 2023, with an anticipated end date of August 22, 2025. The study will adhere to all regulatory requirements to ensure the safety and well-being of participants while providing valuable insights into the treatment of hypercholesterolemia with MK-0616.

The clinical trial involves the administration of **MK-0616**, an experimental medication, to evaluate its efficacy and safety in adults with **hypercholesterolemia**. **MK-0616** is provided in the form of a **film-coated tablet** and is administered orally. The dosage is set at a maximum of 20 mg per day, with a total maximum dose of 7300 mg over the course of the study. The treatment period extends up to 52 weeks. The active substance, **MK-0616**, is of chemical origin and is manufactured by Merck & Co. Inc. Participant compliance with the dosing schedule will be monitored throughout the trial to ensure adherence to the protocol.

In addition to the experimental treatment, a **placebo** is used as a comparator in this double-blind, placebo-controlled study. The placebo consists of microcrystalline cellulose, sodium chloride, and magnesium stearate. It is also administered in a form that mimics the experimental medication, ensuring blinding is maintained. The placebo is administered orally, following the same dosing schedule as the experimental treatment, to maintain consistency across the study arms. The use of a placebo allows for the assessment of the true efficacy and safety profile of **MK-0616** by providing a baseline for comparison.

The efficacy of MK-0616 in the treatment of **hypercholesterolemia** will be assessed through a Phase 3, randomized, double-blind, placebo-controlled clinical trial. The primary efficacy endpoint is the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24. Secondary endpoints include the percent change from baseline in LDL-C at Week 52, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), and lipoprotein A [Lp(A)]. Additionally, the percentage of participants achieving LDL-C levels below 70 mg/dL and 55 mg/dL with a ≥50% reduction from baseline will be evaluated.

Efficacy parameters will be measured at specified timepoints, including Week 24 and Week 52, using validated laboratory tests to determine cholesterol levels. The data collected will be analyzed to compare the efficacy of MK-0616 against placebo in reducing LDL-C and other lipid parameters. The trial aims to confirm the safety and efficacy of MK-0616 in adults with hypercholesterolemia, with the estimated end date of the study being August 22, 2025.